Pangua Cristina, Rogado Jacobo, Serrano-Montero Gloria, Belda-Sanchís José, Álvarez Rodríguez Beatriz, Torrado Laura, Rodríguez De Dios Nuria, Mielgo-Rubio Xabier, Trujillo Juan Carlos, Couñago Felipe
Department of Medical Oncology, Hospital Universitario Infanta Leonor, Madrid 28031, Spain.
Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau & Hospital de Mar, Universitat Autònoma de Barcelona, Barcelona 08041, Catalonia, Spain.
World J Clin Oncol. 2022 Jun 24;13(6):429-447. doi: 10.5306/wjco.v13.i6.429.
The treatment of small cell lung cancer (SCLC) is a challenge for all specialists involved. New treatments have been added to the therapeutic armamentarium in recent months, but efforts must continue to improve both survival and quality of life. Advances in surgery and radiotherapy have resulted in prolonged survival times and fewer complications, while more careful patient selection has led to increased staging accuracy. Developments in the field of systemic therapy have resulted in changes to clinical guidelines and the management of patients with advanced disease, mainly with the introduction of immunotherapy. In this article, we describe recent improvements in the management of patients with SCLC, review current treatments, and discuss future lines of research.
小细胞肺癌（SCLC）的治疗对所有相关专科医生来说都是一项挑战。近几个月来，新的治疗方法已被纳入治疗手段，但仍须继续努力以提高生存率和生活质量。手术和放疗的进展使生存时间延长且并发症减少，同时更谨慎的患者选择提高了分期的准确性。全身治疗领域的发展导致了临床指南的改变以及晚期疾病患者管理方式的变化，主要是由于免疫疗法的引入。在本文中，我们描述了SCLC患者管理方面的近期进展，回顾了当前的治疗方法，并讨论了未来的研究方向。
